State IA
Clinical Trials in Iowa
Recruiting clinical trials with at least one study location in Iowa. Data updated daily from ClinicalTrials.gov.
Top Conditions in Iowa
Chronic Lymphocytic Leukemia (4)Non-small Cell Lung Cancer (3)Stage IVB Prostate Cancer AJCC v8 (3)Small Lymphocytic Lymphoma (3)COVID-19 (3)Head and Neck Squamous Cell Carcinoma (2)Oral Cavity Squamous Cell Carcinoma (2)Stage I Lip and Oral Cavity Cancer AJCC v8 (2)Stage II Lip and Oral Cavity Cancer AJCC v8 (2)Multiple Myeloma (2)Crohn's Disease (2)Stage IV Lung Cancer AJCC v8 (2)
Frequently Asked Questions — Clinical Trials in Iowa
How many clinical trials are currently recruiting in Iowa?
ClinicalMetric currently tracks 134 actively recruiting clinical trials with at least one location in Iowa. The total number of registered studies—including active but not currently enrolling trials—is 134. Trial availability is updated daily from ClinicalTrials.gov, and new studies open enrollment regularly throughout the year.
What types of clinical trials are available in Iowa?
Iowa hosts clinical trials across a broad range of medical conditions, including Chronic Lymphocytic Leukemia, Non-small Cell Lung Cancer, Stage IVB Prostate Cancer AJCC v8, and many others. Trials range from Phase 1 early-safety studies to Phase 4 post-approval surveillance, as well as observational and behavioral research. Academic medical centers, community hospitals, and specialized research clinics throughout Iowa serve as trial sites for studies sponsored by NIH, pharmaceutical companies, and independent investigators.
How do I join a clinical trial near me in Iowa?
To join a clinical trial in Iowa, browse the recruiting studies listed on this page, review the eligibility criteria for each trial, and contact the study site directly. Your primary care physician or specialist can also refer you to clinical trials relevant to your diagnosis. Many academic medical centers in Iowa maintain dedicated clinical trials offices that can match you with appropriate studies based on your medical profile and diagnosis.
Recruiting Trials in Iowa
NCT06503367 N/A
Recruiting
Observation Study in Patients Age 0-5 Years With LAMA2-related Congenital Muscul...
Condition
LAMA2-MD \(Merosin Deficient Congenital Muscular Dystrophy, MDC1A\)
Enrollment
44 pts
Location
United States
Sponsor
Nationwide Children's Hospital
NCT06673589 N/A
Recruiting
Brain-to-brain Synchrony in Ss With Different Levels of Social Interaction
Condition
Social Dynamics
Enrollment
30 pts
Location
United States
Sponsor
Maharishi International Univer
NCT06632457 Phase 3
Recruiting
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a L...
Condition
Metabolic Dysfunction Associated Steatohepatitis
Enrollment
1,590 pts
Location
United States, Argentina, Australia
Sponsor
Boehringer Ingelheim
NCT06058377 Phase 3
Recruiting
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy T...
Condition
Anatomic Stage II Breast Cancer AJCC v8
Enrollment
3,680 pts
Location
United States, Puerto Rico
Sponsor
National Cancer Institute (NCI
NCT03488693 Phase 3
Recruiting
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer
Condition
Breast Cancer
Enrollment
2,140 pts
Location
United States, Canada
Sponsor
Canadian Cancer Trials Group
NCT05503264 Phase 3
Recruiting
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodyn...
Condition
NMDAR Autoimmune Encephalitis
Enrollment
152 pts
Location
United States, Argentina, Austria
Sponsor
Hoffmann-La Roche
NCT05874921 N/A
Recruiting
uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Canc...
Condition
Urothelial Carcinoma
Enrollment
400 pts
Location
United States
Sponsor
UroGen Pharma Ltd.
NCT03232918 Phase 4
Recruiting
Oxytocin and Fetal Heart Rate Changes
Condition
Fetal Bradycardia Complicating Labor and Delivery
Enrollment
730 pts
Location
United States
Sponsor
Unyime Ituk
NCT04509050 N/A
Recruiting
Study to Evaluate Biological & Clinical Effects of Significantly Corrected CFTR ...
Condition
Cystic Fibrosis
Enrollment
210 pts
Location
United States
Sponsor
Sonya Heltshe
NCT05135091 Phase 3
Recruiting
Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Tempo...
Condition
Mesial Temporal Lobe Epilepsy
Enrollment
88 pts
Location
United States
Sponsor
Neurona Therapeutics
NCT06588478 Phase 2
Recruiting
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With...
Condition
Chronic Lymphocytic Leukemia
Enrollment
249 pts
Location
United States, Australia, Belgium
Sponsor
Loxo Oncology, Inc.
NCT07293936 N/A
Recruiting
Post-Filter Hematocrit
Condition
Continuous Renal Replacement Therapy
Enrollment
20 pts
Location
United States
Sponsor
Gwyndolyn M. Radford
NCT04566328 Phase 3
Recruiting
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Mu...
Condition
Plasma Cell Myeloma
Enrollment
1,450 pts
Location
United States, Puerto Rico
Sponsor
ECOG-ACRIN Cancer Research Gro
NCT06422923 Phase 1, Phase 2
Recruiting
A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral...
Condition
Epilepsy, Temporal Lobe
Enrollment
10 pts
Location
United States
Sponsor
Neurona Therapeutics
NCT05457283 Phase 3
Recruiting
A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-t...
Condition
Chronic Kidney Disease
Enrollment
100 pts
Location
United States, Argentina, Australia
Sponsor
Bayer
NCT05654922 Phase 3
Recruiting
Study to Evaluate ARINA-1 in the Prevention of Bronchiolitis Obliterans Progress...
Condition
Pre-Bronchiolitis Obliterans Syndrome
Enrollment
100 pts
Location
United States
Sponsor
Renovion, Inc.
NCT04919382 Phase 2
Recruiting
Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastati...
Condition
Extensive Stage Lung Small Cell Carcinoma
Enrollment
56 pts
Location
United States
Sponsor
Dwight Owen
NCT06136559 Phase 3
Recruiting
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of I...
Condition
Chronic Lymphocytic Leukemia
Enrollment
1,200 pts
Location
United States, Australia, Belgium
Sponsor
Merck Sharp & Dohme LLC
NCT06084806 Phase 2
Recruiting
Test-retest Evaluation of [18F]F-AraG PET
Condition
Non-small Cell Lung Cancer
Enrollment
10 pts
Location
United States
Sponsor
CellSight Technologies, Inc.
NCT07166406 Phase 3
Recruiting
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Pat...
Condition
Advanced Hepatocellular Carcinoma
Enrollment
226 pts
Location
United States
Sponsor
NRG Oncology
NCT06739122 Phase 3
Recruiting
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants W...
Condition
Type 2 Diabetes
Enrollment
55 pts
Location
United States, Argentina, Mexico
Sponsor
Eli Lilly and Company
NCT06958536 Phase 2
Recruiting
A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's...
Condition
Crohn's Disease
Enrollment
99 pts
Location
United States, Australia, Belgium
Sponsor
Sanofi
NCT05489705 N/A
Recruiting
A Prospective Registry Study to Assess Real-world Patient Characteristics, Treat...
Condition
Obstructive Hypertrophic Cardiomyopathy
Enrollment
1,600 pts
Location
United States, Austria, France
Sponsor
Bristol-Myers Squibb
NCT05334069 N/A
Recruiting
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests...
Condition
Acute Lymphoblastic Leukemia
Enrollment
2,000 pts
Location
United States
Sponsor
Alliance for Clinical Trials i
NCT04970901 Phase 1
Recruiting
A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirin...
Condition
B-Cell Non-Hodgkin Lymphoma
Enrollment
200 pts
Location
United States, Belgium, Czechia
Sponsor
ADC Therapeutics S.A.
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology